TuHURA Plans Phase 3 Accelerated Approval Trial in Merkel Cell Carcinoma

 IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)

Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibody

Advancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma

Early discovery programs designing first-in-class tumor microenvironment modulating bi-specific antibody drug conjugates (ADCs) or peptide drug conjugates (PDCs) targeting Myeloid Derived Suppressor Cells (MDSCs)

Company expands leadership team with key clinical and regulatory appointments to drive strategy and operational execution

https://www.accesswire.com/946558/tuhurabiosciencesincnasdaqhuraoutlinesdevelopmentpathwayforsinglephase3acceleratedapprovalregistrationtrialinfirstlinetreatmentofadvancedormetastaticmerkelcellcarcinomaandprovidesbusinessupdate